Ophthotech OPH2003 – Actively Enrolling
This a phase 2a study for fovea-sparing dry age related macular degeneration with unifocal or multifocal atrophy. It is studying intravitreal injections of a drug called Zimura by way of anti-complement C5 mechanism. This study started in January 2016 and the estimated completion date is April 2019.
ZIMURA – Actively Enrolling
To assess the safety of intravitreal Zimura™ (complement factor C5 inhibitor) administered in combination with Lucentis® 0.5 mg in treatment naïve subjects with neovascular age related macular degeneration (NVAMD).
EyeArt – Actively Enrolling
More than 29 million people in the US are living with diabetes, many of whom will develop diabetic retinopathy (DR) or diabetic macular edema (DME) collectively known as diabetic eye disease (DED), the leading cause of vision loss and blindness in working-age adults. Annual eye screening is recommended for all diabetic patients since vision loss can be prevented with laser photocoagulation and anti-VEGF treatment if DR is diagnosed in its early stages. Currently, the number of clinical personnel trained for DR screening is orders of magnitude smaller than that needed to screen the large, growing diabetic population. Therefore, to meet this large unmet need for DR screening, a fully-automated computerized DR screening system is necessary.
EyeArt is an automated screening device designed automatically analyze color fundus photographs of diabetic patients to identify patients with referable or vision threatening DED. This study is designed to assess the safety and efficacy of EyeArt.
Ophthea – Actively Enrolling
A multicentre, randomised, parallel group, sham-controlled, double-masked, dose-ranging study, investigating two doses of OPT-302 in combination with ranibizumab compared with ranibizumab with sham, over six consecutive monthly dosing cycles in participants with neovascular (wet) AMD.
Alcon Extension – Actively Enrolling
The purpose of this study is to collect data on safety and efficacy of the brolucizumab 6 mg drug product intended for commercialization in patients with neovascular age-related macular degeneration (nAMD) and to support comparability to the 6 mg drug product used in Phase III.
Allergan Sequoia – Enrollment Closed
This is a phase 3 study for patients with treatment naive wet age related macular degeneration. This study is evaluating intravitreal abicipar (DARPin based anti-angiogenic drug), in comparison to intravitreal anti-VEGF ranibizmuab (Lucentis) injections. The estimated enrollment is 900 patients. The study started around June 2015, and will end around May 2019.
Alcon Hawk (RTH 258-C001) – Enrollment Closed
This is a phase 3 randomized double-masked randomized study for patients with treatment-naive wet age-related macular degeneration. It is studying two doses of an intravitreal antibody fragment called RTH258 in comparison to traditional monthly intravitreal aflibercept (Eylea) injections. The study length is two years and estimated to include 1,600 patients. The study started in December 2014, and the estimated study completion date is May 2018.
If you would like to participate in our research program please contact our Research Coordinator at 909-335-8938 or firstname.lastname@example.org